Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...
In the future, the most effective cancer drug therapies will likely be combinations that not only target cancer cells but also drive cancer-suppressing responses in non-cancer cells in and around...
Researchers are reporting an impressive advance in the treatment of mantle cell lymphoma, a type of blood cancer that is considered incurable. Patients who took the drug ibrutinib in addition to a...
Cancer “adjuvant” therapies are treatments designed to reduce the chances of tumors coming back after surgery. But for decades, attempts to find adjuvant treatments for kidney cancer failed to...
Researchers have verified a much-needed new target for treating cancers that often become resistant to existing therapies and become deadly. In an early-phase clinical trial, the researchers tested...
Cancer immunotherapies called checkpoint inhibitors can bring dramatic, life-saving results – but only for a limited fraction of patients. Aiming to help more patients benefit, researchers in...
Cancer researchers say they have established a new, life-extending treatment option for men with prostate cancer that has spread and become resistant to hormone therapy. The injected treatment...
Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to...
Cancer researchers have discovered a way to target a pivotal driver of drug resistance in ovarian cancer, one of the top causes of cancer death in women. The experimental compound, called SU056,...
Conventional anti-clotting drugs have a big downside: increased risk of internal bleeding. An entirely new class of antithrombotic developed at OHSU and its spin-off biopharmaceutical company,...